For research purposes only — These compounds aren't FDA approved. All data presented is from clinical trials for educational reference.
BPC-157
Regenerative Peptide
Dosage
Quantity
Price
$29.99
Free shipping on orders $150+
60-day money-back guarantee
Secure checkout
Made in the USA
Certificate of Analysis
Batch verified lab data
99.93%
Purity
- Variant
- BPC-157 5mg
- Lot #
- A0112
- Labeled
- 20mg
- Actual
- 22.56mg
- Tested
- Feb 4, 2026
Frequently Researched Together
View allResearch Purposes Snapshot
Educational reference from preclinical work and sparse human reporting. Evidence is weighted toward animal models; larger trials are still needed. Not FDA approved for therapeutic use.
Research status
Where BPC-157 sits in the literature
- Origin
- Peptide sequence from human gastric juice
- Historic research hub
- University of Zagreb, Croatia
- Clinical development
- Phase 1 completed (check registry for current arms)
- Regulatory framing
- Unapproved drug (U.S.) — research use only
Verify active trial status on ClinicalTrials.gov.
200+
Publications
Peer-reviewed papers indexed since the early 1990s in multiple model systems.
7×
GHR signal
Growth hormone receptor expression reported ~7-fold by day 3 in some tissue models.
7/12
Human pain signal
Small knee cohort: 7 of 12 subjects described relief past six months in summaries.
No LD50
Acute tox screens
Standard rodent toxicology packages often fail to reach a classical lethal dose.
14–21 d
Typical study window
Many preclinical readouts cluster in the two- to three-week range.
Growth pathway
GHR upregulation & repair context
Literature links BPC-157 to higher growth-hormone receptor expression and downstream cytoskeletal remodeling cues that support fibroblast behavior in explant models.
- GHR expression (day 3)
- ~7×
- FAK phosphorylation
- Dose-dependent ↑
- Paxillin activation
- Enhanced
- Cell migration
- Up to ~70% faster
Evidence synthesis
2025 systematic review lens
Recent umbrella-style reviews cite dozens of studies yet emphasize that human samples remain tiny compared with animal datasets.
Dose-dependent gains in migration, FAK/paxillin phosphorylation, and stress survival are recurring themes in tendon fibroblast papers (e.g. J Appl Physiol, 2011).
Cross-check figures against NIH-indexed systematic reviews (2025).
Outcome spread
How often models report benefit
Percentages summarize published narratives, not individualized predictions. Human data remain narrow.
Healing time deltas
vs untreated controls (preclinical)
Bars show approximate relative time-to-heal reductions described in injury-model summaries (J Appl Physiol, 2011).
Domains explored in research
Musculoskeletal
Tendon healing
Fibroblast outgrowth, collagen synthesis, FAK-paxillin activation.
Gut & liver
GI protection
Stable in gastric juice for 24+ h in lab assays; ulcer, colitis, fistula models.
Brain–gut axis
Neuro modulation
Dopamine/serotonin tone, TBI and spinal cord injury rodent data.
Orthopedics
Bone repair
Enhanced bone-defect healing in rabbit studies.
Musculoskeletal detail
- Tendon fibroblast outgrowth ≈ +85% vs control explants
- Transwell migration ≈ +70%
- H₂O₂ stress survival ≈ +60%
J Appl Physiol (2011).
GI tract
- Gastric ulcer acceleration
- Colitis inflammation reduction
- Fistula and anastomosis repair models
World J Gastroenterol (and related).
Neuroprotection
- Monoamine modulation
- TBI lesion volume reductions
- SCI functional gains in rats
Neural Regen Res / Curr Neuropharmacol.
Stacked research angles
BPC-157 + TB-500 (TB-4 fragment)
Literature often contrasts complementary mechanisms: BPC-157 leaning on VEGFR2/angiogenic programs versus TB family peptides influencing actin organization and motility.
- BPC-157 emphasis
- VEGFR2 / angiogenesis axis
- TB-500 emphasis
- Actin dynamics / cell motility
Overlap: both are discussed as anti-inflammatory modulators in animal injury models.
Combination protocols appear frequently in preclinical discussion because pathways appear orthogonal—always map claims back to primary sources.
Safety profile from research
Preclinical breadth vs thin human exposure.
Mild, localized complaints
Local irritation
MildGI discomfort
MildTheoretical angiogenesis caution
Pro-angiogenic biology raises hypothetical tumor-growth questions that are not resolved by public oncology trials—treat as a research planning flag, not a diagnosis.
- No dedicated cancer outcome studies cited in mainstream summaries
- Long-term human surveillance remains thin
Toxicology table (preclinical)
- LD50
- Not reached
- Acute toxicity
- None observed
- Chronic (6 mo)
- No signal in packages cited
- Organ panels
- No consistent injury pattern
Human exposure notes
Pilot IV work (10–20 mg) in two adults reportedly showed stable safety labs in conference/summary narratives— confirm against the primary manuscript.
- WADA banned S0 class (2022)
- DoD prohibited dietary supplement list mention
- AU/NZ scheduling treats as Rx-only—still not a consumer approval
Regulatory & sourcing reality
- FDA considers related products unapproved drugs when marketed for human use.
- Gray-market quality swings remain a documented risk—certificate programs matter for labs.
- Pregnancy, lactation, and pediatrics lack controlled data.
Storage handling reference
Peptide handling
Cold
Lyophilized: refrigerate or freeze per SOP.
Dry
Reconstitute with sterile technique.
Light
Limit UV exposure during prep.
Aliquot
Avoid repeated freeze-thaw cycles.
Researcher notes
- Preclinical safety volume is large, yet prospective human trials remain small.
- Recent IV pilot reporting (10–20 mg, two adults) described no acute lab perturbations—validate in the primary paper.
- Third-party testing (HPLC/MS, endotoxin) is critical when sourcing non-clinical material.
Important Research Notice
Not for human consumption. This product and all products are sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from journals and official publications but should be fact checked. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations and you do not intend to use it for human consumption.